Telix, ANMI to Jointly Develop, Commercialize Prostate Cancer Imaging Agent
News
Australia’s Telix Pharmaceuticals has entered a partnership with Belgium’s Advanced Nuclear Medicine Ingredients (ANMI) to commercialize ANMI’s 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit, used for prostate cancer imaging, in the United States. “Prostate cancer affects one ... Read more